Meta-analyses confirms that loss of IFN-γ signalling in tumour cells caused resistance to immune effector cells in vitro, made tumours more susceptible to the host immune system in vivo, and patient tumours developing mutations in IFN-γ signalling before treatment were more likely to respond to ICBT. This evidence concerns the gene IFNG and neoplasm.